Here's what your DNA tells us about you.
We looked across your genetic markers to find where your biology and specific peptides line up, and which ones may help. Each recommendation shows two things: the strength of the published science behind the compound, and how that compound connects to your DNA.
Summary cards grouped by category from your genetic findings.
Your personalized peptide protocol
8 compounds matched to your genetics, ranked by score.
Tirzepatide
Compound evidence: Tier 1, strong clinicalMatched to your genotypeYour DNA points to: Increased appetite / energy intake; Type 2 diabetes risk; GLP-1/GIP GI side-effect risk. Tirzepatide has evidence for this (evidence strength: strong).
Dual GLP-1/GIP agonist; glycemic control and substantial weight reduction.
Route: Subcutaneous · Dose: 2.5-15 mg
Actual dosing should be determined by your provider.
Dulaglutide
Compound evidence: Tier 1, strong clinicalGene-level evidenceYour MC4R, TCF7L2 variants relate to weight, which Dulaglutide targets.
Weekly GLP-1 receptor agonist for type 2 diabetes.
Route: Subcutaneous · Dose: 0.75-4.5 mg
Actual dosing should be determined by your provider.
Exenatide
Compound evidence: Tier 1, strong clinicalGene-level evidenceYour MC4R, TCF7L2 variants relate to weight, which Exenatide targets.
First-generation GLP-1 receptor agonist (exendin-4 analog); glycemic control and modest weight loss.
Route: Subcutaneous · Dose: 5-10 mcg (BID) or 2 mg weekly
Actual dosing should be determined by your provider.
Liraglutide
Compound evidence: Tier 1, strong clinicalGene-level evidenceYour DNA points to: Type 2 diabetes risk. Liraglutide has evidence for this (evidence strength: moderate to strong).
Daily GLP-1 receptor agonist; appetite and glycemic control.
Route: Subcutaneous · Dose: 0.6-3.0 mg
Actual dosing should be determined by your provider.
Semaglutide
Compound evidence: Tier 1, strong clinicalGene-level evidenceYour DNA points to: Increased appetite / energy intake; Type 2 diabetes risk. Semaglutide has evidence for this (evidence strength: strong).
GLP-1 receptor agonist; appetite regulation and glycemic control.
Route: Subcutaneous · Dose: 0.25-2.4 mg
Actual dosing should be determined by your provider.
Cerebrolysin
Compound evidence: Tier 3, pathway-supportedGene-level evidenceYour DNA points to: Reduced BDNF / memory; Elevated homocysteine / methylation insufficiency. Cerebrolysin has evidence for this (evidence strength: limited).
Porcine-derived neuropeptide preparation; studied for stroke recovery, TBI and dementia with mixed-to-positive trial data.
Route: Intravenous / Intramuscular · Dose: 5-30 mL
Actual dosing should be determined by your provider.
NAD+
Compound evidence: Tier 3, pathway-supportedGene-level evidenceYour NQO1 variant relates to longevity, which NAD+ targets.
Supporting precursors: NMN, NR (folded under NAD+).
Cellular cofactor; mitochondrial energy and sirtuin activity. Note: NAD+ is a cellular cofactor (dinucleotide), not a peptide; offered under the peptide-therapy umbrella.
Route: IV / SubQ / oral precursors · Dose: 100-500 mg
Actual dosing should be determined by your provider.
Semax
Compound evidence: Tier 4, preclinicalGene-level evidenceYour DNA points to: Reduced BDNF / memory; Prefrontal dopamine tone / executive function; Serotonergic / drug-response tendency. Semax has evidence for this (evidence strength: limited).
Nootropic peptide; raises BDNF/NGF, neuroprotective.
Route: Intranasal · Dose: 300-600 mcg
Actual dosing should be determined by your provider.
A few things to watch based on your DNA.
Genotype associated with adverse / reduced-response or tolerability risk for this compound.
Evidence for this variant's effect is mixed/contested — consider it a discussion point with your provider, not a firm recommendation.
Evidence for this variant's effect is mixed/contested — consider it a discussion point with your provider, not a firm recommendation.
Evidence for this variant's effect is mixed/contested — consider it a discussion point with your provider, not a firm recommendation.
Evidence for this variant's effect is mixed/contested — consider it a discussion point with your provider, not a firm recommendation.
Ready to build your protocol?
5 compounds selected. Prescription medications require a licensed provider. Research compounds are shown for educational purposes only and are not available to order. Add the ones you want to discuss and send the list to your provider for review.